Biotech Stocks: short review to Biogen Biotechnology company, stocks and market in 2022

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB.

It reported full-year revenues totaling $13.4 billion, a 6% decrease over the previous year. In 2021, it faces what it terms a “financial reset” with the introduction of a generic version of its most-prescribed MS drug therapy.

Biogen competitors include Johnson & Johnson, Emergent Biosolutions, Pfizer, Gilead Sciences and Amgen.

Biogen is an excellent company to work for. I feel that they are well-rounded in providing a good work-life balance, competitive compensation, and an inclusive work environment. There are several avenues to be able to move up the ranks. The only thing that concerns me is job security.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

%d bloggers like this: